As a Med Honors Top Pharmaceutical Innovator, Bristol-Myers Squibb (BMS) has made significant contributions to the fields of oncology and immunology, developing transformative treatments that have redefined patient care. The company's pioneering work in immunotherapies has been particularly impactful, offering new hope to patients with various forms of cancer.

A cornerstone of BMS's oncology portfolio is Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor designed to harness the body's immune system to restore anti-tumor responses. Opdivo has become an important treatment option across multiple cancers, including advanced hepatocellular carcinoma.

In the realm of immunology, BMS has been researching immune disorders for more than 20 years, discovering and developing therapies that help regulate the body's immune response.

BMS continues to innovate, exploring the potential of subcutaneous immunotherapy formulations to reduce treatment burden and enhance healthcare efficiencies. This approach aims to provide patients with more convenient treatment options without compromising efficacy.

With a steadfast commitment to scientific excellence and patient-centric innovation, Bristol-Myers Squibb remains at the forefront of medical advancements, solidifying its position as a Med Honors Top Pharmaceutical Innovator.